➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
AstraZeneca
Boehringer Ingelheim
Moodys
Baxter

Last Updated: July 10, 2020

DrugPatentWatch Database Preview

Patent: RE37336

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: RE37336
Title: Method for providing hyaluronic acid
Abstract:Disclosed are DNA segments encoding .[.hyaluronic acid synthase which are employed to construct recombinant cells useful in the production of hyaluronate synthase or hyaluronic acid (HA).]. .Iadd.the recombinant DNA segment identified in FIG. 5. .Iaddend.In preferred aspects, chromosomal DNA from Streptococcus equisimilis is partially digested with EcoRI and the resultant fragments are ligated to form recombinant vectors. These vectors are useful in the transformation of host cells such as E. coli and or Streptococcal hosts. .[.Resultant transformants are screened by the novel screening assays to identify colonies which have incorporated HA synthase DNA in a form that is being actively transcribed into the corresponding HA synthase enzyme. These colonies may be selected and employed in the production of the enzyme itself or its product, HA..]. .Iadd.The recombinant DNA segment identified in FIG. 5 is then inserted into a recombinant Streptococcal host for the production of hyaluronic acid (HA)..Iaddend.
Inventor(s): Weigel; Paul H. (Edmond, OK), Papaconstantinou; John (Galveston, TX)
Assignee: The Board of Regents of the University of Oklahoma (Norman, OK)
Application Number:09/281,107
Patent Claims:see list of patent claims

Details for Patent RE37336

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Akorn Inc HYDASE hyaluronidase INJECTABLE;INJECTION 021716 001 2005-10-25   Start Trial The Board of Regents of the University of Oklahoma (Norman, OK) 2040-03-31 DISCN search
Amphastar Pharm AMPHADASE hyaluronidase INJECTABLE;INJECTION 021665 001 2005-11-03   Start Trial The Board of Regents of the University of Oklahoma (Norman, OK) 2040-03-31 RX search
Bausch And Lomb VITRASE hyaluronidase INJECTABLE;INJECTION 021640 002 2004-12-21   Start Trial The Board of Regents of the University of Oklahoma (Norman, OK) 2040-03-31 RX search
Bausch And Lomb VITRASE hyaluronidase INJECTABLE;INJECTION 021640 001 2004-12-21   Start Trial The Board of Regents of the University of Oklahoma (Norman, OK) 2040-03-31 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Baxter
Johnson and Johnson
Dow
Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.